PL3833358T3 - Zastosowanie ligandów agonistycznych receptora igf-2 w leczeniu zespołu angelmana i autyzmu - Google Patents
Zastosowanie ligandów agonistycznych receptora igf-2 w leczeniu zespołu angelmana i autyzmuInfo
- Publication number
- PL3833358T3 PL3833358T3 PL19846073.5T PL19846073T PL3833358T3 PL 3833358 T3 PL3833358 T3 PL 3833358T3 PL 19846073 T PL19846073 T PL 19846073T PL 3833358 T3 PL3833358 T3 PL 3833358T3
- Authority
- PL
- Poland
- Prior art keywords
- autism
- igf
- treatment
- receptor agonist
- angelman syndrome
- Prior art date
Links
- 208000009575 Angelman syndrome Diseases 0.000 title 1
- 206010003805 Autism Diseases 0.000 title 1
- 208000020706 Autistic disease Diseases 0.000 title 1
- 102000038460 IGF Type 2 Receptor Human genes 0.000 title 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862717372P | 2018-08-10 | 2018-08-10 | |
| PCT/US2019/046227 WO2020033971A1 (en) | 2018-08-10 | 2019-08-12 | Use of igf-2 receptor agonist ligands for treatment of angelman syndrome and autism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3833358T3 true PL3833358T3 (pl) | 2024-03-04 |
Family
ID=69415274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19846073.5T PL3833358T3 (pl) | 2018-08-10 | 2019-08-12 | Zastosowanie ligandów agonistycznych receptora igf-2 w leczeniu zespołu angelmana i autyzmu |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12083139B2 (pl) |
| EP (2) | EP4356964A3 (pl) |
| JP (2) | JP7466927B2 (pl) |
| KR (1) | KR20210075068A (pl) |
| CN (1) | CN113164501B (pl) |
| AU (1) | AU2019319296B2 (pl) |
| BR (1) | BR112021002456A2 (pl) |
| CA (1) | CA3109137A1 (pl) |
| ES (1) | ES2966930T3 (pl) |
| MX (2) | MX2021001595A (pl) |
| PL (1) | PL3833358T3 (pl) |
| WO (1) | WO2020033971A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021001596A (es) | 2018-08-10 | 2021-06-08 | Univ New York | Uso de manosa-6-fosfato y sus modificaciones para mejorar la memoria y reducir el daño mental. |
| US20230145514A1 (en) * | 2020-04-24 | 2023-05-11 | New York University | Use of igf-2 for treatment of epileptic seizures |
| US12178853B2 (en) * | 2020-10-13 | 2024-12-31 | Betavive Ltd. | Method and compounds for treating diabetes and associated metabolic diseases |
| US12447198B2 (en) | 2021-10-12 | 2025-10-21 | Betavive Ltd. | Peptides and fragments for treating diabetes and associated metabolic diseases |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE139699T1 (de) | 1988-08-19 | 1996-07-15 | Univ Australian | Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel |
| GB9516012D0 (en) | 1995-08-04 | 1995-10-04 | Univ Manchester | Pharmaceutical composition |
| US6093388A (en) * | 1996-08-12 | 2000-07-25 | Btg International Limited | Mannose-6-phosphate composition and its use in treating fibrotic disorders |
| AUPO309896A0 (en) * | 1996-10-18 | 1996-11-14 | Australian National University, The | Novel phosphosugars and phosphosugar-containing compounds having anti-inflammatory activity |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7666843B2 (en) | 2002-09-27 | 2010-02-23 | Children's Medical Center Corporation | Methods and compositions for treatment of neurological disorder |
| CN1660125A (zh) | 2004-12-16 | 2005-08-31 | 南开大学 | 大豆异黄酮增强和改善记忆的新性能及其应用 |
| GB0516722D0 (en) * | 2005-08-15 | 2005-09-21 | Cancer Rec Tech Ltd | Methods and materials |
| PL2019683T5 (pl) | 2006-04-25 | 2022-12-05 | The Regents Of The University Of California | Podawanie czynników wzrostu do leczenia zaburzeń OUN |
| US20100081613A1 (en) | 2006-10-11 | 2010-04-01 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for enhancing memory |
| AR064464A1 (es) * | 2006-12-22 | 2009-04-01 | Genentech Inc | Anticuerpos anti - receptor del factor de crecimiento insulinico |
| FR2930942B1 (fr) * | 2008-05-07 | 2011-03-04 | Centre Nat Rech Scient | Nouvelles utilisations de derives de d-mannopyranose activateurs de l'angiogenese |
| EP2424542A4 (en) * | 2009-04-28 | 2012-12-19 | Pharmaxis Ltd | PHOSPHOTETRAHYDROPYRAN COMPOUNDS FOR THE TREATMENT OF WOUNDS AND FIBROTIC ILLNESSES |
| WO2011000958A1 (en) * | 2009-07-03 | 2011-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
| GB0916332D0 (en) | 2009-09-17 | 2009-10-28 | Renovo Ltd | Medicaments |
| US20120266263A1 (en) | 2009-10-14 | 2012-10-18 | Mount Sinai School Of Medicine | Method of treating memory disorders and enhancing memory using igf-ii compounds |
| WO2011127194A1 (en) * | 2010-04-06 | 2011-10-13 | The George Washington University | Compositions and methods for identifying autism spectrum disorders |
| WO2013119964A2 (en) * | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| EP2928300A4 (en) * | 2012-11-28 | 2016-07-13 | Neuren Pharmaceuticals Ltd | TREATMENT OF AUTISTIC DISEASES WITH GLYCYL-L-2-METHYLPROLYL-L-GLUTAMINE ACID |
| US20150224164A1 (en) * | 2013-11-26 | 2015-08-13 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid |
| EP3377065B1 (en) | 2015-11-17 | 2022-05-18 | Merck Sharp & Dohme Corp. | Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors |
| MX2021001596A (es) | 2018-08-10 | 2021-06-08 | Univ New York | Uso de manosa-6-fosfato y sus modificaciones para mejorar la memoria y reducir el daño mental. |
-
2019
- 2019-08-12 PL PL19846073.5T patent/PL3833358T3/pl unknown
- 2019-08-12 JP JP2021506933A patent/JP7466927B2/ja active Active
- 2019-08-12 EP EP23212830.6A patent/EP4356964A3/en not_active Withdrawn
- 2019-08-12 BR BR112021002456-5A patent/BR112021002456A2/pt unknown
- 2019-08-12 CA CA3109137A patent/CA3109137A1/en active Pending
- 2019-08-12 ES ES19846073T patent/ES2966930T3/es active Active
- 2019-08-12 EP EP19846073.5A patent/EP3833358B1/en active Active
- 2019-08-12 MX MX2021001595A patent/MX2021001595A/es unknown
- 2019-08-12 CN CN201980066500.6A patent/CN113164501B/zh active Active
- 2019-08-12 AU AU2019319296A patent/AU2019319296B2/en active Active
- 2019-08-12 WO PCT/US2019/046227 patent/WO2020033971A1/en not_active Ceased
- 2019-08-12 KR KR1020217007050A patent/KR20210075068A/ko not_active Ceased
- 2019-08-12 US US17/267,715 patent/US12083139B2/en active Active
-
2021
- 2021-02-09 MX MX2023014556A patent/MX2023014556A/es unknown
-
2024
- 2024-03-27 JP JP2024050725A patent/JP2024081724A/ja active Pending
- 2024-08-06 US US18/796,218 patent/US20240390405A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2966930T3 (es) | 2024-04-25 |
| EP4356964A2 (en) | 2024-04-24 |
| US12083139B2 (en) | 2024-09-10 |
| EP3833358A1 (en) | 2021-06-16 |
| MX2023014556A (es) | 2023-12-14 |
| EP3833358A4 (en) | 2022-04-13 |
| CN113164501B (zh) | 2024-08-09 |
| EP4356964A3 (en) | 2024-06-19 |
| US20210315914A1 (en) | 2021-10-14 |
| AU2019319296A1 (en) | 2021-03-25 |
| KR20210075068A (ko) | 2021-06-22 |
| US20240390405A1 (en) | 2024-11-28 |
| CA3109137A1 (en) | 2020-02-13 |
| JP7466927B2 (ja) | 2024-04-15 |
| JP2024081724A (ja) | 2024-06-18 |
| WO2020033971A1 (en) | 2020-02-13 |
| AU2019319296B2 (en) | 2024-09-12 |
| EP3833358B1 (en) | 2023-12-06 |
| JP2021534125A (ja) | 2021-12-09 |
| BR112021002456A2 (pt) | 2021-05-04 |
| MX2021001595A (es) | 2021-06-08 |
| CN113164501A (zh) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275936A (en) | Variants of type IIB activin receptor and methods of using them | |
| IL278546B2 (en) | Activin receptor type IIA variants and methods of using them | |
| IL268966A (en) | Glycan-interacting compounds and methods of use | |
| IL259713B2 (en) | Anti-DR5 antibodies and methods of using them | |
| IL277174A (en) | Therapeutic combination of 1-4 BB agonists with anti-CD20 antibodies | |
| IL259660B (en) | Apelin receptor agonists and methods of use | |
| PL3467482T3 (pl) | Sposoby i system do oceny wydajności operacji czyszczenia | |
| IL269077A (en) | Anti-gitr antibodies and methods of use thereof | |
| SG11201913596XA (en) | Loading apparatus and physical vapor deposition apparatus | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| IL273848A (en) | Anti-cd40 antibodies for use in the treatment of Sjögren's syndrome | |
| IL270245B (en) | A device and method for managing capacity usage | |
| IL288803A (en) | tgf-beta receptors and methods of use | |
| IL277212A (en) | Anti-KLK5 antibodies and methods of use | |
| IL265342A (en) | Use of pridofidine for the treatment of Rett syndrome | |
| IL273538A (en) | Anti-TRKB Monoclonal Antibodies and Methods of Use | |
| IL281208A (en) | Chronic nocturnal dosing of lasmiditan for migraine prevention | |
| GB2587246B (en) | Methods and systems for characterizing multiple properties of cement using p-waves of multiple frequencies | |
| IL274161A (en) | Systems and methods for the treatment of hyper-IGM syndrome | |
| GB2573856B (en) | Dispenser system and method of use | |
| ZA202002144B (en) | Antibodies and methods of use | |
| GB202009064D0 (en) | Compounds and methods of use | |
| GB201807452D0 (en) | Internet-based system and method of use thereof | |
| SG11202105573PA (en) | Methods of treating myelodysplastic syndrome | |
| HUE054756T2 (hu) | Alkoholfogyasztáshoz kapcsolódó rendellenességek kezelése |